Silence Therapeutics (NASDAQ:SLN) Issues Quarterly Earnings Results

by · The Cerbat Gem

Silence Therapeutics (NASDAQ:SLN – Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.27) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.06, FiscalAI reports. Silence Therapeutics had a negative net margin of 254.25% and a negative return on equity of 61.76%. The firm had revenue of $0.03 million for the quarter, compared to analysts’ expectations of $2.19 million.

Silence Therapeutics Price Performance

SLN stock opened at $5.50 on Friday. Silence Therapeutics has a one year low of $1.97 and a one year high of $7.78. The stock has a market cap of $259.79 million, a price-to-earnings ratio of -4.07 and a beta of 1.32. The company has a fifty day moving average price of $5.32 and a two-hundred day moving average price of $5.75.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. Wall Street Zen upgraded Silence Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. William Blair reiterated an “outperform” rating on shares of Silence Therapeutics in a research note on Monday. Weiss Ratings reissued a “sell (d-)” rating on shares of Silence Therapeutics in a report on Thursday, January 22nd. Finally, Jefferies Financial Group restated a “buy” rating on shares of Silence Therapeutics in a report on Thursday. Five research analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $34.50.

View Our Latest Analysis on Silence Therapeutics

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of SLN. Nantahala Capital Management LLC lifted its position in Silence Therapeutics by 48.0% during the fourth quarter. Nantahala Capital Management LLC now owns 1,542,427 shares of the company’s stock worth $9,378,000 after acquiring an additional 500,000 shares during the last quarter. Millennium Management LLC increased its stake in shares of Silence Therapeutics by 121.0% during the fourth quarter. Millennium Management LLC now owns 659,592 shares of the company’s stock worth $4,010,000 after purchasing an additional 361,080 shares during the period. Opaleye Management Inc. acquired a new stake in Silence Therapeutics during the 4th quarter worth approximately $480,000. UBS Group AG boosted its stake in Silence Therapeutics by 34.5% in the 3rd quarter. UBS Group AG now owns 307,363 shares of the company’s stock valued at $1,595,000 after purchasing an additional 78,854 shares during the period. Finally, Marshall Wace LLP grew its holdings in Silence Therapeutics by 87.1% in the 4th quarter. Marshall Wace LLP now owns 155,680 shares of the company’s stock valued at $947,000 after buying an additional 72,461 shares in the last quarter. 98.73% of the stock is owned by institutional investors.

About Silence Therapeutics

(Get Free Report)

Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence’s technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities.

The company’s lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism.

Featured Stories